Mabwell (shanghai) Bioscience Co., Ltd.

This early-phase trial is testing an experimental drug called 7MW4911 in 200 people with advanced colorectal or other gastrointestinal cancers that have progressed after standard treatments. The main goals are to find a safe dose and to see if the drug can shrink tumors. It is th…

This study is testing two experimental drugs, 7MW3711 and JS207, given together (with or without chemotherapy) in people with advanced solid tumors that have stopped responding to standard treatments. The trial has two phases: first, finding the safest dose, then checking how wel…

This study tests a new drug called 7MW4911 in 200 people with advanced solid tumors that have worsened after standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. It is the first time this drug is being tested in human…

This study tests whether combining two drugs (9MW2821 and toripalimab) before and after surgery can improve outcomes for people with urothelial cancer (a type of bladder cancer). About 90 adults with non-spread cancer will receive the treatment and be monitored for tumor shrinkag…

This study tests an experimental drug called 9MW1911 in 360 adults with moderate-to-severe COPD. The goal is to see if it can reduce the number of serious flare-ups over one year compared to a placebo. Participants must be 40-75 years old, have had at least two moderate or one se…

This early-phase trial is testing a new drug called bulumtatug furvedotin (BFv) in 52 people with triple-negative breast cancer that has come back or spread to other parts of the body. Participants must have already received certain types of chemotherapy and antibody-drug conjuga…

This study tests a new drug called 9MW3811 for people with thick, raised scars that haven't improved in 6 months. About 30 adults will receive either the drug or a placebo to see if it makes scars look and feel better. The goal is to reduce scar thickness, color, pain, and itchin…